Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
IRLAB Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
IRLAB Therapeutics's earnings have been declining at an average annual rate of -13.5%, while the Pharmaceuticals industry saw earnings growing at 9.9% annually. Revenues have been growing at an average rate of 19.3% per year.
Anahtar bilgiler
-13.5%
Kazanç büyüme oranı
-7.7%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 30.5% |
Gelir büyüme oranı | 19.3% |
Özkaynak getirisi | -171.4% |
Net Marj | -287.3% |
Sonraki Kazanç Güncellemesi | 30 Oct 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?
Jun 06Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation
Jan 04Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely
Sep 21We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully
Mar 18IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans
Dec 01We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit
May 19We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Sep 11We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow
Apr 30What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Mar 19We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth
Jan 25Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay
Dec 21What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?
Nov 25Gelir ve Gider Dağılımı
IRLAB Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 42 | -119 | 56 | 0 |
31 Mar 24 | 6 | -157 | 43 | 0 |
31 Dec 23 | 6 | -178 | 53 | 0 |
30 Sep 23 | 19 | -176 | 44 | 0 |
30 Jun 23 | 36 | -162 | 45 | 0 |
31 Mar 23 | 52 | -144 | 54 | 0 |
31 Dec 22 | 61 | -113 | 42 | 0 |
30 Sep 22 | 61 | -103 | 39 | 0 |
30 Jun 22 | 240 | 42 | 37 | 0 |
31 Mar 22 | 217 | 43 | 35 | 0 |
31 Dec 21 | 208 | 52 | 31 | 0 |
30 Sep 21 | 196 | 55 | 27 | 0 |
30 Jun 21 | 0 | -93 | 24 | 0 |
31 Mar 21 | 0 | -93 | 24 | 0 |
31 Dec 20 | 0 | -92 | 24 | 0 |
30 Sep 20 | 0 | -99 | 23 | 0 |
30 Jun 20 | 0 | -93 | 23 | 0 |
31 Mar 20 | 1 | -98 | 11 | 0 |
31 Dec 19 | 0 | -96 | 22 | 0 |
30 Sep 19 | 1 | -88 | 21 | 0 |
30 Jun 19 | 1 | -83 | 21 | 0 |
31 Mar 19 | 0 | -76 | 20 | 0 |
31 Dec 18 | 0 | -74 | 18 | 0 |
30 Sep 18 | 0 | -68 | 20 | 0 |
30 Jun 18 | 0 | -73 | 19 | 0 |
31 Mar 18 | 0 | -60 | 27 | 0 |
31 Dec 17 | 0 | -56 | 15 | 0 |
30 Sep 17 | 0 | -58 | 13 | 0 |
30 Jun 17 | 0 | -48 | 15 | 0 |
31 Mar 17 | 3 | -44 | 14 | 0 |
31 Dec 16 | 3 | -43 | 14 | 0 |
31 Dec 15 | 3 | -12 | 10 | 0 |
31 Dec 14 | 3 | 3 | 5 | 0 |
Kaliteli Kazançlar: IRLAB A is currently unprofitable.
Büyüyen Kar Marjı: IRLAB A is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: IRLAB A is unprofitable, and losses have increased over the past 5 years at a rate of 13.5% per year.
Büyüme Hızlandırma: Unable to compare IRLAB A's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: IRLAB A is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.5%).
Özkaynak Getirisi
Yüksek ROE: IRLAB A has a negative Return on Equity (-171.41%), as it is currently unprofitable.